应用核酸分离纯化、蛋白分离提取、质粒扩增与提取、PCR、SDS-PAGE电泳、免疫印迹、免疫共沉淀、酶联免疫等技术，从基因、蛋白等分子水平阐释呼吸疾病的病理生理及药物作用机制。

（1）Shao Dong, Liu Xinguang, Wu Jinyan, Zhang Ang, Bai Yunping, Zhao Peng, Li Jiansheng. Identification of the active compounds and functional mechanisms of Jinshui Huanxian formula in pulmonary fibrosis by integrating serum pharmacochemistry with network pharmacology. Phytomedicine. 2022; 102:154177.

（2）Zhao Peng, Cai Zehui, Tian Yange, Li Junzi, Li Kangchen, Li Minyan, Bai Yunping, Li Jiansheng. Effective-compound combination inhibits the M2-like polarization of macrophages and attenuates the development of pulmonary fibrosis by increasing autophagy through mTOR signaling. Int Immunopharmacol. 2021; 101(Pt B):108360.

（3）Liu Lan, Qin Yanqin, Cai Zehui, Tian Yange, Liu Xuefang, Li Jiansheng, Zhao Peng. Effective-components combination improves airway remodeling in COPD rats by suppressing M2 macrophage polarization via the inhibition of mTORC2 activity. Phytomedicine. 2021;92: 153759.

（4）Bai Yunping, Li Jiansheng, Zhao Peng, Li Ya, Li Meng, Feng Suxiang, Qin Yanqin, Tian Yange, Zhou Tiqiang. A Chinese Herbal Formula Ameliorates Pulmonary Fibrosis by Inhibiting Oxidative Stress via Upregulating Nrf2. Front Pharmacol. 2018; 9: 628.

（5）Zhao Peng, Li Jiansheng, Tian Yange, Mao Jing, Liu Xuefang, Feng Suxiang, Li Junzi, Bian Qingqing, Ji Huige, Zhang Lanxi. Restoring Th17/Treg balance via modulation of STAT3 and STAT5 activation contributes to the amelioration of chronic obstructive pulmonary disease by Bufei Yishen formula. J Ethnopharmacol. 2018; 217:152-162.

（1）国家自然科学基金面上项目，81973822，基于组分配伍探讨补肺益肾方阻抑炎症反应治疗COPD机制，李建生，2020.01-2023.12，56.00万元。

（2）国家自然科学基金面上项目，81673942，基于调控TGF-β1/wnt/β-catenin与PPARγ通路的金水缓纤方治疗肺纤维化的机制，李建生，2017.01-2020.12，66.00万元。

（3）国家自然科学基金重点项目，81130062，调补肺肾三法调控多维分子网络治疗COPD 的作用及远后效应，李建生，2012.01-2016.12，260.00万元。

（1）补肺益肾方激活A2aR调节Th17/Treg平衡改善慢阻肺

（2）补肺益肾组分方抑制mTOR阻抑巨噬细胞M2极化改善慢阻肺气道重塑

（3）金水缓纤方激活Nrf2抑制氧化应激改善肺纤维化